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Microglia: a novel treatment target in gliomas 
 
Microglial cells have not received too much attention in Neuro-Oncology over the last 
decades, despite the fact that they may be the most abundant cell within the glioma 
tissue. Accordingly, Neuro-Oncology now devoted a major review article on the 
changing concepts of what microglial cells do or do not do, both in the normal and 
diseased brain, with a focus on the biology of gliomas (1). 
Traditionally, microglial cells have been considered part of the immune system, but it 
had remained controversial to what extent these cells are capable of antigen 
presentation and participation in immune responses. Their origin, local resident brain 
cell versus bone marrow-derived, has been one focus of microglia research for years, 
and it now seems clear that the microglial cell population especially in the disease 
state is likely to derive from both cellular sources. 
The current view sees microglial cells not as an efficient arm of the immune system, 
but rather a misguided host cell population abused by the growing glioma for its own 
advantage. Microglial cells are attracted to the site of tumor growth and expanded 
locally by signaling molecules such as monocyte chemoattractant protein 1, 
macrophage colony-stimulating factor, vascular endothelial growth factor and 
placental growth factor. These factors are not only released by glioma cells, but 
presumably also by the microenvironment that is constantly shaped by these tumors. 
Thus, microglial cells are now thought to support invasiveness by the release of 
matrix metalloproteases, angiogenesis by the release of proangiogenic factors, and 
immunosuppression. The latter is mediated by the conversion of microglial cells, 
respectively macrophages recruited from the periphery, into the M2 macrophage 
phenotype which is characterized by the release of immunosuppressive, e.g. 
interleukin 10, rather than immunostimulastory cytokines, e.g. tumor necrosis factor- 
or interferon-, less nitric oxide production, and poor antigen presentation. These 
changes in the microglia/macrophage phenotype, in turn, are thought to be controlled 
by soluble factors such as transforming growth factor-β which interact with their 
respective receptors expressed on microglial cells. 
Altogether, these considerations may lead to new treatment approaches for 
glioblastoma that focus not only on the glioma cells proper, but raise the perspective 
of trying to contain glioma growth by modulating its microenvironment, notably its 
permissiveness for immune responses against the tumor. Thus, any immunotherapy 
will work better if the M2 phenotype of microglial cells and macrophages can be 
(re)converted to a M1 phenotype. 
Finally, if microglial cells are indeed in part bone marrow-derived and exhibit efficient 
homing into the brain, cellular therapy strategies might adopt some of the pathways 
mediating this specific cellular trafficking between periphery and central nervous 
system to deliver therapeutic payloads to the intracranial tumor sites or even directly 
use engineered, reprogrammed microglial cells for such purposes. 
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